CD79b-vcMMAE efficacy is not blunted by somatic mutations or cell doubling time. (A) In vitro doubling time does not correlate with anti–CD79b-vcMMAE activity. (B) Anti–CD79b-vcMMAE has potent in vitro activity in both TP53 mutant and wild-type cell lines. (C) Anti–CD79b-vcMMAE in vitro activity is not perturbed by somatic mutations in common oncogenes.